On the sites of antitsive action of N-(2-picolyl)-N-phenyl-N-(2-piperidinoethyl)amine (TAT-3).
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000996:Antitussive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D001565:Benzoates / Q000494:pharmacology; D001665:Binding Sites; D001835:Body Weight / Q000187:drug effects; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects; D003061:Codeine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003371:Cough / Q000517:prevention & control*; D003655:Decerebrate State; D003864:Depression, Chemical; D004285:Dogs; D004558:Electric Stimulation; D005071:Evoked Potentials / Q000187:drug effects; D006801:Humans; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D007823:Laryngeal Nerves / Q000187:drug effects; D007977:Levallorphan / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D010276:Parasympatholytics / Q000494:pharmacology; D012018:Reflex / Q000187:drug effects; D012119:Respiration / Q000187:drug effects; D011984:Sensory Receptor Cells / Q000187:drug effects; D013268:Stimulation, Chemical; D013375:Substance Withdrawal Syndrome; D014132:Trachea / Q000187:drug effects
D000996:Antitussive Agents; D001565:Benzoates; D010276:Parasympatholytics; D007977:Levallorphan; D003061:Codeine